Download Data in NIH Biosketch Format

OMB No. 0925-0001 and 0925-0002 (Rev. 10/15 Approved Through 10/31/2018)
BIOGRAPHICAL SKETCH
DO NOT EXCEED FIVE PAGES.
NAME: Bates, E. R.
eRA COMMONS USER NAME (credential, e.g., agency login):
POSITION TITLE:
EDUCATION/TRAINING (Begin with baccalaureate or other initial professional education, such as nursing,
include postdoctoral training and residency training if applicable. Add/delete rows as necessary.)
INSTITUTION AND LOCATION
DEGREE
(if
applicable)
Completion
Date
MM/YYYY
FIELD OF STUDY
A. Personal Statement
B. Positions and Honors
Positions and Employment
Other Experience and Professional Memberships
Honors
C. Contribution to Science
Brener, S. J., Lincoff, A. M., Bates, E. R., Jia, G., Armstrong, P. W., Guetta, V., Hochman, J. S., Savonitto, S.,
Wilcox, R. G., White, H. D., Topol, E. J., Investigators, Gusto V. The relationship between baseline risk and
mortality in st-elevation acute myocardial infarction treated with pharmacological reperfusion: Insights from the
global utilization of strategies to open occluded arteries (gusto) v trial. (2005). American Heart Journal, 150(1),
89-93.
Asher, C. R., Moliterno, D. J., Bhapkar, M. V., McGuire, D. K., Rao, S. V., Holmes, D. R., Newby, L. K., Bates,
E. R., Topol, E. J., Investigators, Symphony & Investigators, 2nd SYMPHONY Association of race with
complications and prognosis fohowing acute coronary syndromes. (2004). American Journal of Cardiology,
94(6), 792-794.
Mehta, R. H., Criger, D. A., Granger, C. B., Pieper, K. K., Califf, R. M., Topol, E. J. & Bates, E. R. Patient
outcomes after fibrinolytic therapy for acute myocardial infarction at hospitals with and without coronary
revascularization capability. (2002). Journal of the American College of Cardiology, 40(6), 1034-1040.
Topol, C. E., Califf, R. M., Simes, R. J., Van de Werf, F., Diaz, R., Paolasso, E., Aylward, P. E., Keech, A.,
Klein, W., Piegas, L., Tomov, I., Armstrong, P. W., et al. Comparison of sibrafiban with aspirin for prevention of
cardiovascular events after acute coronary syndromes: A randomised trial. (2000). Lancet, 355(9201), 337345.
Menon, V., Hochman, J. S., Stebbins, A., Pfisterer, M., Col, J., Anderson, R. D., Hasdai, D., Holmes, D. R.,
Bates, E. R., Topol, E. J., Califf, R. M., Ohman, E. M., et al. Lack of progress in cardiogenic shock: Lessons
from the gusto trials. (2000). European Heart Journal, 21(23), 1928-1936.
Hasdai, D., Califf, R. M., Thompson, T. D., Hochman, J. S., Ohman, E. M., Pfisterer, M., Bates, E. R.,
Vahanian, A., Armstrong, P. W., Criger, D. A., Topol, E. J., Holmes, D. R. Predictors of cardiogenic shock after
thrombolytic therapy for acute myocardial infarction. (2000). Journal of the American College of Cardiology,
35(1), 136-143.
Topol, E. J., Ohman, E. M., Barnathan, E., Califf, R. M., Lee, K. L., Lincoff, A. M., Scherer, J., Scott, R.,
Sketch, M. H., Weisman, H. F., Cantor, W., Evans, B., et al. Trial of abciximab with and without low-dose
reteplase for acute myocardial infarction. (2000). Circulation, 101(24), 2788-2794.
Holmes, D. R., Barger, P. B., Hochman, J. S., Granger, C. B., Thompson, T. D., Califf, R. M., Vahanian, A.,
Bates, E. R. & Topol, E. J. Cardiogenic shock in patients with acute ischemic syndromes with and without stsegment elevation. (1999). Circulation, 100(20), 2067-2073.
Hasdai, D., Holmes, D. R., Topol, E. J., Berger, P. B., Criger, D. A., Hochman, J. S., Bates, E. R., Vahanian,
A., Armstrong, P. W., Wilcox, R., Ohman, E. M., Califf, R. M. Frequency and clinical outcome of cardiogenic
shock during acute myocardial infarction among patients receiving reteplase or alteplase - results from gustoiii. (1999). European Heart Journal, 20(2), 128-135.
Oconnor, C. M., Hathaway, W. R., Bates, E. R., Leimberger, J. D., Sigmon, K. N., Kereiakes, D. J., George, B.
S., Samaha, J. K., Abbottsmith, C. W., Candela, R. J., Topol, E. J., Califf, R. M. Clinical characteristics and
long-term outcome of patients in whom congestive heart failure develops after thrombolytic therapy for acute
myocardial infarction: Development of a predictive model. (1997). American Heart Journal, 133(6), 663-673.
Holmes, D. R., Califf, R. M., VandeWerf, F., Berger, P. B., Bates, E. R., Simoons, M. L., White, H. D.,
Thompson, T. D. & Topol, E. J. Difference in countries' use of resources and clinical outcome for patients with
cardiogenic shock after myocardial infarction: Results from the gusto trial. (1997). Lancet, 349(9045), 75-78.
Berger, P. B., Holmes, D. R., Stebbins, A. L., Bates, E. R., Califf, R. M. & Topol, E. J. Impact of an aggressive
invasive catheterization and revascularization strategy on mortality in patients with cardiogenic shock in the
global utilization of streptokinase and tissue plasminogen activator for occluded coronary arteries (gusto-i) trial
- an observational study. (1997). Circulation, 96(1), 122-127.
Anderson, R. D., Ohman, E. M., Holmes, D. R., Col, J., Stebbins, A. L., Bates, E. R., Stomel, R. J., Granger, C.
B., Topol, E. J. & Califf, R. M. Use of intraaortic balloon counterpulsation in patients presenting with
cardiogenic shock: Observations from the gusto-i study. (1997). Journal of the American College of Cardiology,
30(3), 708-715.
Peterson, E. D., Hathaway, W. R., Zabel, K. M., Pieper, K. S., Granger, C. B., Wagner, G. S., Topol, E. J.,
Bates, E. R., Simoons, M. L. & Califf, R. M. Prognostic significance of precordial st segment depression during
inferior myocardial infarction in the thrombolytic era: Results in 16,521 patients. (1996). Journal of the
American College of Cardiology, 28(2), 305-312.
Holmes, D. R., Bates, E. R., Kleiman, N. S., Sadowski, Z., Horgan, J. H. S., Morris, D. C., Califf, R. M., Berger,
P. B. & Topol, E. J. Contemporary reperfusion therapy for cardiogenic-shock - the gusto-i trial experience.
(1995). Journal of the American College of Cardiology, 26(3), 668-674.
Ohman, E. M., Topol, E. J., Califf, R. M., Bates, E. R., Ellis, S. G., Kereiakes, D. J., George, B. S., Samaha, J.
K., Kline, E., Sigmon, K. N. & Stack, R. S. An analysis of the cause of early mortality after administration of
thrombolytic therapy. (1993). Coronary Artery Disease, 4(11), 957-964.
Topol, E. J., Ellis, S. G., Cosgrove, D. M., Bates, E. R., Muller, D. W. M., Schork, N. J., Schork, M. A. & Loop,
F. D. Analysis of coronary angioplasty practice in the united-states with an insurance-claims data-base. (1993).
Circulation, 87(5), 1489-1497.
Gacioch, G. M., Ellis, S. G., Lee, L., Bates, E. R., Kirsh, M., Walton, J. A. & Topol, E. J. Cardiogenic-shock
complicating acute myocardial-infarction - the use of coronary angioplasty and the integration of the new
support devices into patient-management. (1992). Journal of the American College of Cardiology, 19(3), 647653.
Nabel, E. G., Topol, E. J., Galeana, A., Ellis, S. G., Bates, E. R., Werns, S. W., Walton, J. A., Muller, D. W.,
Schwaiger, M. & Pitt, B. A randomized placebo-controlled trial of combined early intravenous captopril and
recombinant tissue-type plasminogen-activator therapy in acute myocardial-infarction. (1991). Journal of the
American College of Cardiology, 17(2), 467-473.
Clemmensen, P., Bates, E. R., Califf, R. M., Hlatky, M. A., Aronson, L., George, B. S., Lee, K. L., Kereiakes, D.
J., Gacioch, G., Berrios, E. & Topol, E. J. Complete atrioventricular-block complicating inferior wall acute
myocardial-infarction treated with reperfusion therapy. (1991). American Journal of Cardiology, 67(4), 225-230.
Bates, E. R. & Topol, E. J. Limitations of thrombolytic therapy for acute myocardial-infarction complicated by
congestive-heart-failure and cardiogenic-shock. (1991). Journal of the American College of Cardiology, 18(4),
1077-1084.
Ellis, S. G., Bates, E. R., Schaible, T., Weisman, H. F., Pitt, B. & Topol, E. J. Prospects for the use of
antagonists to the platelet glycoprotein-IIb glycoprotein-IIIa receptor to prevent postangioplasty restenosis and
thrombosis. (1991). Journal of the American College of Cardiology, 17(6), B89-B95.
Sane, D. C., Stump, D. C., Topol, E. J., Sigmon, K. N., Clair, W. K., Kereiakes, D. J., George, B. S., Stoddard,
M. F., Bates, E. R., Stack, R. S. & Califf, R. M. Racial-differences in responses to thrombolytic therapy with
recombinant tissue-type plasminogen-activator - increased fibrin(ogen)olysis in blacks. (1991). Circulation,
83(1), 170-175.
Ellis, S. G., Debowey, D., Bates, E. R. & Topol, E. J. Treatment of recurrent ischemia after thrombolysis and
successful reperfusion for acute myocardial-infarction - effect on in-hospital mortality and left-ventricular
function. (1991). Journal of the American College of Cardiology, 17(3), 752-757.
Bates, E. R., Clemmensen, P. M., Califf, R. M., Gorman, L. E., Aronson, L. G., George, B. S., Kereiakes, D. J.
& Topol, E. J. Precordial st segment depression predicts a worse prognosis in inferior infarction despite
reperfusion therapy. (1990). Journal of the American College of Cardiology, 16(7), 1538-1544.
Topol, E. J., Ellis, S. G., Califf, R. M., George, B. S., Stump, D. C., Bates, E. R., Nabel, E. G., Walton, J. A.,
Candela, R. J., Lee, K. L., Kline, E. M., Pitt, B. Combined tissue-type plasminogen-activator and prostacyclin
therapy for acute myocardial-infarction. (1989). Journal of the American College of Cardiology, 14(4), 877-884.
Ellis, S. G., Oneill, W. W., Bates, E. R., Walton, J. A., Nabel, E. G. & Topol, E. J. Coronary angioplasty as
primary therapy for acute myocardial-infarction 6 to 48 hours after symptom onset - report of an initial
experience. (1989). Journal of the American College of Cardiology, 13(5), 1122-1126.
Bates, E. R. & Topol, E. J. Early hospital discharge in the myocardial reperfusion era. (1989). Clinical
Cardiology, 12(7 Suppl 3<br />), 65-70.
Holland, K. J., Oneill, W. W., Bates, E. R., Pitt, B. & Topol, E. J. Emergency percutaneous trans-luminal
coronary angioplasty during acute myocardial-infarction for patients more than 70 years of age. (1989).
American Journal of Cardiology, 63(7), 399-403.
Ellis, S. G., Oneill, W. W., Bates, E. R., Walton, J. A., Nabel, E. G., Werns, S. W. & Topol, E. J. Implications for
patient triage from survival and left-ventricular functional recovery analyses in 500 patients treated with
coronary angioplasty for acute myocardial-infarction. (1989). Journal of the American College of Cardiology,
13(6), 1251-1259.
Ellis, S. G., Gallison, L., Grines, C. L., Langburd, A. B., Bates, E. R., Walton, J. A., Oneill, W. W. & Topol, E. J.
Incidence and predictors of early recurrent ischemia after successful percutaneous trans-luminal coronary
angioplasty for acute myocardial-infarction. (1989). American Journal of Cardiology, 63(5), 263-268.
Bates, E. R., Califf, R. M., Stack, R. S., Aronson, L., George, B. S., Candela, R. J., Kereiakes, D. J.,
Abbottsmith, C. W., Anderson, L., Pitt, B., Oneill, W. W., Topol, E. J. Thrombolysis and angioplasty in
myocardial-infarction (tami-1) trial - influence of infarct location on arterial patency, left-ventricular function and
mortality. (1989). Journal of the American College of Cardiology, 13(1), 12-18.
Grines, C. L., Topol, E. J., Bates, E. R., Juni, J. E., Walton, J. A. & Oneill, W. W. Infarct vessel status after
intravenous tissue plasminogen-activator and acute coronary angioplasty - prediction of clinical outcome.
(1988). American Heart Journal, 115(1), 1-7.
Ellis, S. G., Topol, E. J., Gallison, L., Grines, C. L., Langburd, A. B., Bates, E. R., Walton, J. A. & Oneill, W. W.
Predictors of success for coronary angioplasty performed for acute myocardial-infarction. (1988). Journal of the
American College of Cardiology, 12(6), 1407-1415.
Topol, E. J., Oneill, W. W., Langburd, A. B., Walton, J. A., Bourdillon, P. D. V., Bates, E. R., Grines, C. L.,
Schork, A. M., Kline, E. & Pitt, B. A randomized, placebo-controlled trial of intravenous recombinant tissue-type
plasminogen-activator and emergency coronary angioplasty in patients with acute myocardial-infarction.
(1987). Circulation, 75(2), 420-428.
Topol, E. J., Bates, E. R., Walton, J. A., Baumann, G., Wolfe, S., Maino, J., Bayer, L., Gorman, L., Kline, E. M.,
Oneill, W. W. & Pitt, B. Community-hospital administration of intravenous tissue plasminogen-activator in acute
myocardial-infarction - improved timing, thrombolytic efficacy and ventricular-function. (1987). Journal of the
American College of Cardiology, 10(6), 1173-1177.
Oneill, W. W., Topol, E. J., Fung, A., Bourdillon, P. D. V., Nicklas, J. M., Walton, J., Bates, E. R. & Pitt, B.
Coronary angioplasty as therapy for acute myocardial infarction: University of Michigan experience. (1987).
Circulation, 76(2 Pt 2<br />), 79-87.
Bates, E. R., Topol, E. J., Kline, E. M., Langburd, A. B., Fung, A. Y., Walton, J. A., Bourdillon, P. D. V., Vogel,
R. A., Pitt, B. & Oneill, W. W. Early reperfusion therapy improves left-ventricular function after acute inferior
myocardial-infarction associated with right coronary-artery disease. (1987). American Heart Journal, 114(2),
261-267.
Fung, A. Y., Lai, P., Topol, E. J., Bates, E. R., Bourdillon, P. D. V., Walton, J. A., Mancini, G. B. J., Kryski, T.,
Pitt, B. & Oneill, W. W. Value of percutaneous trans-luminal coronary angioplasty after unsuccessful
intravenous streptokinase therapy in acute myocardial-infarction. (1986). American Journal of Cardiology,
58(9), 686-691.
Complete List of Published Work in MyBibliography: [See the Kresge Library web site for instructions for
populating MyBibliography using VIVO.]
D. Research Support
Ongoing Research Support
Completed Research Support
OMB No. 0925-0001 and 0925-0002 (Rev. 10/15 Approved Through 10/31/2018)
BIOGRAPHICAL SKETCH
Provide the following information for the Senior/key personnel and other significant contributors.
Follow this format for each person. DO NOT EXCEED FIVE PAGES.
NAME:
eRA COMMONS USER NAME (credential, e.g., agency login):
POSITION TITLE:
EDUCATION/TRAINING (Begin with baccalaureate or other initial professional education, such as nursing,
include postdoctoral training and residency training if applicable. Add/delete rows as necessary.)
INSTITUTION AND LOCATION
DEGREE
(if
applicable)
Completion
Date
MM/YYYY
FIELD OF STUDY
NOTE: The Biographical Sketch may not exceed five pages. Follow instructions below.
A. Personal Statement
Briefly describe why you are well-suited for your role(s) in this project. The relevant factors may include:
aspects of your training; your previous experimental work on this specific topic or related topics; your technical
expertise; your collaborators or scientific environment; and/or your past performance in this or related fields.
Note the following additional instructions:







For institutional research training, institutional career development, or research education grant
applications, faculty who are not senior/key persons are encouraged to complete this section, but not
required to do so.
Applicants for dissertation research awards should include a description of their career goals and
intended career trajectory and their interest in the specific areas of research designated in the FOA, in
addition to the information outlined above.
Candidates for Research Supplements to Promote Diversity in Health-Related Research should include
a description of their general scientific achievements and/or interests, as well as specific research
objectives and career goals, in addition to the information outlined above. Indicate any current
source(s) of educational funding.
If there are factors affecting your past productivity that you wish to explain, such as family care
responsibilities, illness, disability, or military service, you may address them in your personal statement.
Indicate if you have published or created research products under another name.
You may mention specific contributions to science that are not included in Section C. Do not present or
expand on materials that should be described in other sections of this biosketch or the application.
Figures, tables and graphics are not allowed.
You may cite up to four publications or research products that highlight your experience and qualifications for
this project. Research products can include audio or video products; conference proceedings such as meeting
abstracts, posters or other presentations; patents; data and research materials; databases; educational aids or
curricula; instruments or equipment; models; protocols; and software or netware.
B. Positions and Honors
List in chronological order positions held since the completion of your most recent degree, concluding
with your present position. High school students and undergraduates may include any previous positions.
For individuals, such as fellowship applicants or career development award candidates, who are not
currently located at the applicant organization, include the expected position at the applicant
organization, with the expected start date.
List any relevant academic and professional achievements and honors. In particular:

Students, postdoctorates, and junior faculty should include scholarships, traineeships, fellowships,
and development awards, as applicable.

Clinicians should include information on clinical licensure and specialty board certification, if
applicable.

Include present membership on any Federal Government public advisory committee.
C. Contribution to Science
Candidates for Research Supplements to Promote Diversity in Health-Related Research who are high
school students, undergraduates, and postbaccalaureates are not required to complete this section.
Briefly describe up to five of your most significant contributions to science. While all applicants may
describe up to five contributions, graduate students and postdoctorates are encouraged to consider
highlighting two or three they consider most significant. Descriptions may include a mention of research
products under development, such as manuscripts that have not yet been accepted for publication.
Each contribution should be no longer than one half page, including citations. These contributions do not
have to be related to this project. For each contribution:
 Indicate the historical background that frames the scientific problem; the central finding(s); the
influence of the finding(s) on the progress of science or the application of those finding(s) to
health or technology; and your specific role in the described work.
 You may cite up to four papers accepted for publication or research products that are relevant to
the contribution.
o Research products can include audio or video products; conference proceedings such as
meeting abstracts, posters or other presentations; patents; data and research materials;
databases; educational aids or curricula; instruments or equipment; models; protocols;
and software or netware.
o These citations do not have to be authored by you.
You may provide a URL to a full list of your published work. This URL must be to a Federal
Government website (a .gov suffix). NIH recommends using My Bibliography. Providing a URL to a list
of published work is not required, and reviewers are not required to look at the list.
D. Research Support
Note the following instructions for specific types of applicants/candidates:


High school students are not required to complete this section.
Applicants for predoctoral and postdoctoral fellowships, dissertation research grants, and
candidates for Research Supplements to Promote Diversity in Health-Related Research from the
undergraduate through postdoctoral levels should use this section to provide information about
their scholastic performance, following the instructions below. In situations where
applicants/candidates in these categories also have research support, they should complete both
parts of this section.
Research Support
For all other individuals required to complete a biosketch, list selected ongoing and completed research
projects for the past three years (Federal or non-Federal support). Briefly indicate the overall goals of the
projects and your responsibilities. Do not include number of person months or direct costs.
Do not confuse “Research Support” with “Other Support.” Though they sound similar, these parts of the
application are very different.

As part of the biosketch section of the application, “Research Support” highlights your
accomplishments, and those of your colleagues, as scientists. This information will be used by
the reviewers in the assessment of each individual’s qualifications for a specific role in the
proposed project, as well as to evaluate the overall qualifications of the research team.
In contrast, “Other Support” information is required for all applications that are selected to receive
grant awards. NIH staff will request complete and up-to-date “other support” information from you
after peer review.
Scholastic Performance
Predoctoral applicants/candidates (including undergraduates and postbaccalaureates): List by institution
and year all undergraduate and graduate courses, with grades. In addition, in the space following the chart,
explain any grading system if other than 1-100, A, B, C, D, F, or 0-4.0. Show levels required for a passing
grade.
Postdoctoral applicants: List by institution and year all undergraduate courses and graduate scientific
and/or professional courses germane to the training sought under this award, with grades. In the space
following the chart, explain any grading system if other than 1-100, A, B, C, D, F, or 0-4.0. Show levels
required for a passing grade.
OMB No. 0925-0001 and 0925-0002 (Rev. 10/15 Approved Through 10/31/2018)
BIOGRAPHICAL SKETCH
DO NOT EXCEED FIVE PAGES.
NAME: Hunt, Morgan Casey
eRA COMMONS USER NAME (credential, e.g., agency login): huntmc
POSITION TITLE: Associate Professor of Psychology
EDUCATION/TRAINING (Begin with baccalaureate or other initial professional education, such as nursing,
include postdoctoral training and residency training if applicable. Add/delete rows as necessary.)
INSTITUTION AND LOCATION
University of California, Berkeley
University of Vermont
University of California, Berkeley
DEGREE
(if
applicable)
Completion
Date
MM/YYYY
B.S
05/1990
Psychology
Ph.D.
05/1996
Postdoctoral
08/1998
Experimental
Psychology
Public Health and
Epidemiology
FIELD OF STUDY
A. Personal Statement
I have the expertise, leadership, training, expertise and motivation necessary to successfully carry out the
proposed research project. I have a broad background in psychology, with specific training and expertise in
ethnographic and survey research and secondary data analysis on psychological aspects of drug addiction.
My research includes neuropsychological changes associated with addiction. As PI or co-Investigator on
several university- and NIH-funded grants, I laid the groundwork for the proposed research by developing
effective measures of disability, depression, and other psychosocial factors relevant to the aging substance
abuser, and by establishing strong ties with community providers that will make it possible to recruit and track
participants over time as documented in the following publications. In addition, I successfully administered the
projects (e.g. staffing, research protections, budget), collaborated with other researchers, and produced
several peer-reviewed publications from each project. As a result of these previous experiences, I am aware
of the importance of frequent communication among project members and of constructing a realistic research
plan, timeline, and budget. The current application builds logically on my prior work. During 2005-2006 my
career was disrupted due to family obligations. However, upon returning to the field I immediately resumed my
research projects and collaborations and successfully competed for NIH support.
1. Merryle, R.J. & Hunt, M.C. (2004). Independent living, physical disability and substance abuse among the
elderly. Psychology and Aging, 23(4), 10-22.
2. Hunt, M.C., Jensen, J.L. & Crenshaw, W. (2007). Substance abuse and mental health among communitydwelling elderly. International Journal of Geriatric Psychiatry, 24(9), 1124-1135.
3. Hunt, M.C., Wiechelt, S.A. & Merryle, R. (2008). Predicting the substance-abuse treatment needs of an
aging population. American Journal of Public Health, 45(2), 236-245. PMCID: PMC9162292 Hunt, M.C.,
Newlin, D.B. & Fishbein, D. (2009). Brain imaging in methamphetamine abusers across the life-span.
Gerontology, 46(3), 122-145.
B. Positions and Honors
Positions and Employment
1998-2000
Fellow, Division of Intramural Research, National Institute of Drug Abuse, Bethesda, MD
2000-2002
Lecturer, Department of Psychology, Middlebury College, Middlebury, VT
2001Consultant, Coastal Psychological Services, San Francisco, CA
2002-2005
Assistant Professor, Department of Psychology, Washington University, St. Louis, MO
2007Associate Professor, Department of Psychology, Washington University, St. Louis, MO
Other Experience and Professional Memberships
1995Member, American Psychological Association
1998Member, Gerontological Society of America
1998Member, American Geriatrics Society
2000Associate Editor, Psychology and Aging
2003Board of Advisors, Senior Services of Eastern Missouri
2003-05
NIH Peer Review Committee: Psychobiology of Aging, ad hoc reviewer
2007-11
NIH Risk, Adult Addictions Study Section, members
Honors
2003
2004
2009
Outstanding Young Faculty Award, Washington University, St. Louis, MO
Excellence in Teaching, Washington University, St. Louis, MO
Award for Best in Interdisciplinary Ethnography, International Ethnographic Society
C. Contribution to Science
1. My early publications directly addressed the fact that substance abuse is often overlooked in older adults.
However, because many older adults were raised during an era of increased drug and alcohol use, there
are reasons to believe that this will become an increasing issue as the population ages. These
publications found that older adults appear in a variety of primary care settings or seek mental health
providers to deal with emerging addiction problems. These publications document this emerging problem
but guide primary care providers and geriatric mental health providers to recognize symptoms, assess the
nature of the problem and apply the necessary interventions. By providing evidence and simple clinical
approaches, this body of work has changed the standards of care for addicted older adults and will
continue to provide assistance in relevant medical settings well into the future. I served as the primary
investigator or co-investigator in all of these studies.
a. Gryczynski, J., Shaft, B.M., Merryle, R., & Hunt, M.C. (2002). Community based participatory
research with late-life addicts. American Journal of Alcohol and Drug Abuse, 15(3), 222-238.
b. Shaft, B.M., Hunt, M.C., Merryle, R., & Venturi, R. (2003). Policy implications of genetic
transmission of alcohol and drug abuse in female nonusers. International Journal of Drug Policy,
30(5), 46-58.
c. Hunt, M.C., Marks, A.E., Shaft, B.M., Merryle, R., & Jensen, J.L. (2004). Early-life family and
community characteristics and late-life substance abuse. Journal of Applied Gerontology, 28(2),2637.
d. Hunt, M.C., Marks, A.E., Venturi, R., Crenshaw, W. & Ratonian, A. (2007). Community-based
intervention strategies for reducing alcohol and drug abuse in the elderly. Addiction, 104(9), 14361606. PMCID: PMC9000292
2. In addition to the contributions described above, with a team of collaborators, I directly documented the
effectiveness of various intervention models for older substance abusers and demonstrated the importance
of social support networks. These studies emphasized contextual factors in the etiology and maintenance
of addictive disorders and the disruptive potential of networks in substance abuse treatment. This body of
work also discusses the prevalence of alcohol, amphetamine, and opioid abuse in older adults and how
networking approaches can be used to mitigate the effects of these disorders.
a. Hunt, M.C., Merryle, R. & Jensen, J.L. (2005). The effect of social support networks on morbidity
among elderly substance abusers. Journal of the American Geriatrics Society, 57(4), 15-23.
b. Hunt, M.C., Pour, B., Marks, A.E., Merryle, R. & Jensen, J.L. (2005). Aging out of methadone
treatment. American Journal of Alcohol and Drug Abuse, 15(6), 134-149.
c. Merryle, R. & Hunt, M.C. (2007). Randomized clinical trial of cotinine in older nicotine addicts. Age
and Ageing, 38(2), 9-23. PMCID: PMC9002364
3. Methadone maintenance has been used to treat narcotics addicts for many years but I led research that
has shown that over the long-term, those in methadone treatment view themselves negatively and they
gradually begin to view treatment as an intrusion into normal life. Elderly narcotics users were shown in
carefully constructed ethnographic studies to be especially responsive to tailored social support networks
that allow them to eventually reduce their maintenance doses and move into other forms of therapy. These
studies also demonstrate the policy and commercial implications associated with these findings.
a. Hunt, M.C. & Jensen, J.L. (2003). Morbidity among elderly substance abusers. Journal of the
Geriatrics, 60(4), 45-61.
b. Hunt, M.C. & Pour, B. (2004). Methadone treatment and personal assessment. Journal Drug
Abuse, 45(5), 15-26.
c. Merryle, R. & Hunt, M.C. (2005). The use of various nicotine delivery systems by older nicotine
addicts. Journal of Ageing, 54(1), 24-41. PMCID: PMC9112304
d. Hunt, M.C., Jensen, J.L. & Merryle, R. (2008). The aging addict: ethnographic profiles of the elderly
drug user. NY, NY: W. W. Norton & Company.
Complete List of Published Work in MyBibliography:
http://www.ncbi.nlm.nih.gov/sites/myncbi/collections/public/1PgT7IEFIAJBtGMRDdWFmjWAO/?sort=d
ate&direction=ascending
D. Research Support
Ongoing Research Support
R01 DA942367
Hunt (PI)
09/01/08-08/31/16
Health trajectories and behavioral interventions among older substance abusers
The goal of this study is to compare the effects of two substance abuse interventions on health outcomes in an
urban population of older opiate addicts.
Role: PI
R01 MH922731
Merryle (PI)
12/15/07-11/30/15
Physical disability, depression and substance abuse in the elderly
The goal of this study is to identify disability and depression trajectories and demographic factors associated
with substance abuse in an independently-living elderly population.
Role: Co-Investigator
Faculty Resources Grant, Washington University
08/15/09-08/14/15
Opiate Addiction Database
The goal of this project is to create an integrated database of demographic, social and biomedical information
for homeless opiate abusers in two urban Missouri locations, using a number of state and local data sources.
Role: PI
Completed Research Support
R21 AA998075
Hunt (PI)
01/01/11-12/31/13
Community-based intervention for alcohol abuse
The goal of this project was to assess a community-based strategy for reducing alcohol abuse among older
individuals.
Role: PI